IRVINE, Calif., July 29 /PRNewswire-FirstCall/ -- Endologix, Inc.
(Nasdaq: ELGX), developer of minimally invasive treatments for
aortic disorders, announced today that it has received U.S. Food
and Drug Administration (FDA) approval for its new PowerFit™ Aortic
Extensions. The PowerFit extensions are designed to provide
physicians with enhanced visibility under fluoroscopy to facilitate
precise device placement during completion of the Anatomical
Fixation endovascular repair of abdominal aortic aneurysm (AAA).
In addition, PowerFit's independent stent design and 24
circumferential contact points were shown in anatomical simulation
studies to aid in proximal conformability and sealing.
John McDermott, President and
Chief Executive Officer said, "The new PowerFit line of aortic
extensions enhances our expanding product offering, with the added
benefits of improved visibility during placement and design
features that facilitate anatomical conformability and sealing. In
conjunction with anatomical fixation using the IntuiTrak
Endovascular System, and our recently launched new sizes, Endologix
offers a comprehensive product offering for the treatment of AAA.
We look forward to the full U.S. market launch of PowerFit and our
new sizes during the fourth quarter."
PowerFit is designed for use with Endologix's existing products,
including Powerlink® main body bifurcated stent grafts and the
IntuiTrak® Endovascular System. It will be available in a range of
sizes indicated to treat aortic necks ranging from 18 to 32
millimeters in diameter. In addition, the PowerFit product line
will be available with longer stent lengths of up to 120
millimeters, to expand the treatment options for physicians and
their patients. PowerFit will initially be launched through a
limited market release during the third quarter of 2010, followed
by a full U.S. market release during the fourth quarter of 2010.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's flagship product is
the Powerlink® System, which is an endovascular stent graft for the
treatment of abdominal aortic aneurysms (AAA). AAA is a weakening
of the wall of the aorta, the largest artery in the body, resulting
in a balloon-like enlargement. Once AAA develops, it continues to
enlarge and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for ruptured AAA is
approximately 75%, making it a leading cause of death in the U.S.
Additional information can be found on Endologix's Web site at
www.endologix.com.
Forward-Looking Statements
Except for historical information contained herein, this news
release contains forward-looking statements, the accuracy of which
are necessarily subject to risks and uncertainties, all of which
are difficult or impossible to predict accurately and many of which
are beyond the control of Endologix. Many factors may cause actual
results to differ materially from anticipated results, including
the success of sales efforts for the Powerlink System and related
new products, product research and development efforts, and other
economic, business, competitive and regulatory factors. The Company
undertakes no obligation to update its forward looking statements.
Please refer to the Company's Annual Report on Form 10-K for the
year ended December 31, 2009, and the
Company's other filings with the Securities and Exchange
Commission, for more detailed information regarding these risks and
other factors that may cause actual results to differ materially
from those expressed or implied.
COMPANY
CONTACT:
|
INVESTOR
CONTACTS:
|
|
Endologix, Inc.
|
The Ruth Group
|
|
John McDermott, CEO
|
Nick Laudico (646)
536-7030
|
|
(949) 595-7200
|
Zack Kubow (646)
536-7020
|
|
www.endologix.com
|
|
|
|
|
SOURCE Endologix, Inc.